Robotic Resection of Type I Hilar Cholangiocarcinoma with Intrapancreatic Bile Duct Dissection

• Published in: Annals of surgical oncology 2022-02, Vol.29 (2), p.964-969
• Main Authors: Tee, May C., Brahmbhatt, Rushin D., Franko, Jan
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Bile Duct Neoplasms - surgery; Bile ducts; Bile Ducts, Intrahepatic; Biopsy; Cancer; Cholangiocarcinoma; Cholangiocarcinoma - surgery; Complications; Dissection; Gemcitabine; Hepatectomy; Hepatobiliary Tumors; Humans; Jaundice; Klatskin Tumor - surgery; Lymph nodes; Male; Malignancy; Medicine; Medicine & Public Health; Middle Aged; Oncology; Postoperative; Radiation therapy; Robotic Surgical Procedures; Robotics; Surgery; Surgical Oncology; Tumors
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-021-10811-7

Background Type I hilar cholangiocarcinoma is a malignancy of the extrahepatic bile duct for which margin-negative resection with sufficient lymphadenectomy may provide curative treatment. The aim of this video is to highlight the advantages of optical magnification, articulating instruments, and indocyanine green fluorescent cholangiography to demonstrate extrahepatic bile duct resection from the biliary confluence to the intrapancreatic bile duct with comprehensive hilar lymphadenectomy for pathologic staging. Methods A 58-year-old male presented with obstructive jaundice and was found to have a biliary stricture arising from the cystic duct and bile duct junction. Endoscopic biopsy of the bile duct confirmed adenocarcinoma. His case was presented at a multidisciplinary tumor conference where consensus was to proceed with upfront robotic en bloc extrahepatic bile duct resection with hilar lymphadenectomy and Roux-en-Y hepaticojejunostomy. Results Final pathology demonstrated margin-negative resection of moderately differentiated adenocarcinoma, 1 out of 12 lymph nodes involved with disease, and pathologic stage T2N1M0 (stage IIIC). The patient had no postoperative complications and was discharged home on postoperative day 5. At 6 weeks from his operative date, he was initiated on four cycles of adjuvant gemcitabine/capecitabine, followed by 50 Gray external beam radiation therapy with capecitabine, then four cycles of gemcitabine/capecitabine, completed after 6 months of therapy. Conclusions Robotic extrahepatic bile duct resection, hilar lymphadenectomy, and biliary enteric reconstruction is feasible and should be considered for selected cases of bile duct resection.